Back to search
FDAFDA · Food and drugs·Recall number D-0796-2020

Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)

Published January 29, 2020 · Recall initiated: January 7, 2020

Summary

FDA records drug Class II recall D-0796-2020, published January 29, 2020 and initiated January 7, 2020. Recalling firm: Preferred Pharmaceuticals, Inc; Status: Terminated; Reported quantity: 221,710 tablets; Lot: Lot #: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc
Distributor
Distribution to physicians in the following states: AL, AZ, CA, FL, GA, IN, and SC
Lot
Lot #: All lots within expiry
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1) recalled?

Yes. FDA published recall D-0796-2020 on January 29, 2020. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone